A Case of Microscopic Polyangiitis Complicated by Mucormycosis: A Dangerous Balancing Act

Microscopic polyangiitis (MPA) is a rare antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis marked by renal involvement, which often leads to rapidly progressive glomerulonephritis. Immunosuppressive treatment is necessary to prevent irreparable organ damage. On the other hand, mucormycosis is a rare and devastating opportunistic fungal infection with a high mortality rate in both immunosuppressed and immunocompetent individuals. It requires a high index of suspicion at the time of diagnosis since any delay in treatment may lead to severe morbidity or death. Here, we present the case of a diabetic patient diagnosed with MPA who received partial induction treatment, subsequently developed mucormycosis, survived, yet required continued immunosuppressive treatment for active MPA while imaging was concerning for a persistent mucormycosis infection. This case highlights the barriers to early mucormycosis detection specific to vasculitis patients, mucormycosis considerations unique to the rheumatologic population, and discusses how to balance immunosuppressive treatment in the setting of a deadly opportunistic infection.

[1]  P. Merkel,et al.  2022 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for microscopic polyangiitis , 2022, Annals of the Rheumatic Diseases.

[2]  Arnold Lee Avacopan: First Approval , 2021, Drugs.

[3]  G. Guyatt,et al.  2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Antineutrophil Cytoplasmic Antibody–Associated Vasculitis , 2021, Arthritis care & research.

[4]  J. C. Cohen Tervaert,et al.  Avacopan for the treatment of ANCA-associated vasculitis , 2021, Expert review of clinical immunology.

[5]  A. Meara,et al.  ANCA-Associated Vasculitis: An Update , 2021, Journal of clinical medicine.

[6]  A. Chakrabarti,et al.  Global Epidemiology of Mucormycosis , 2019, Journal of fungi.

[7]  B. Spellberg Mucormycosis pathogenesis: Beyond Rhizopus , 2017, Virulence.

[8]  S. Kanekar,et al.  Looks like a stroke, acts like a stroke, but it's more than a stroke: a case of cerebral mucormycosis. , 2014, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[9]  X. Puéchal,et al.  Mucormycosis in systemic autoimmune diseases. , 2014, Joint, bone, spine : revue du rhumatisme.

[10]  R. Afshar,et al.  Rhino-orbitocerebral mucormycosis in a patient with idiopathic crescentic glomerulonephritis. , 2013, Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia.

[11]  C. Menkes,et al.  Mucormycosis cerebral arteritis mimicking a flare in ANCA-associated vasculitis. , 2013, Lancet. Infectious Diseases (Print).

[12]  D. Kontoyiannis,et al.  How I treat mucormycosis. , 2011, Blood.

[13]  D. Kontoyiannis,et al.  Epidemiology and outcome of zygomycosis: a review of 929 reported cases. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[14]  R. Wolfe,et al.  The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. , 2019, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[15]  Sharon A Chung,et al.  Microscopic polyangiitis. , 2010, Rheumatic diseases clinics of North America.